This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Treatment

Authoring team

Treatment of ochronosis includes:

  • most patients are symptomatic and do not require treatment
  • tyrosine and phenylalanine dietary restrictions have been successful for phenylketonuria treatment though it is particularly hard to accomplish, and efficacy is similar to vitamin C megadosing.(1)
  • large joints and heart valves may need replacing

Nitisinone, approved as first-line treatment for the closely related disease, hereditary tyrosinemia, is the only intervention proven to modify disease progression. As such, it is the mainstay of treatment, although its use should be judicious and carefully watched. (2)

Recent advancements in photobiomodulation and photodynamic therapy are new therapies.(3)

Reference

  1. Judd S et al. The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma. JIMD Rep. 2020 May;53(1):45-60
  2. Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol. 2013 May;66(5):367-73.
  3. Bhattar PA et al. Exogenous Ochronosis. Indian J Dermatol. 2015 Nov-Dec;60(6):537-43.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.